Tag archive for ‘Pnina Fishman’

Cipher Pharmaceuticals acquires Canadian rights from Israeli Can-Fite for psoriasis, rheumatoid arthritis treatment

  Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Israeli Can-Fite Biopharma (NYSE MKT: CANF) (TASE: More...

Jewish Business News On Tuesday, February 17th, 2015

Can-Fite Receives Notice of Allowance in US for Psoriasis Patent

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, announced that it has received a Notice of Allowance More...

Can-Fite BioPharma

Can-Fite’s CF101 Trial In Dry Eye Syndrome Fails To Meet Endpoints

– Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging. – CEO Pnina Fishman / Ilan Besor – Can-Fite BioPharma Ltd. ( CANF ) announced today that More...

Ilan Shavit On Tuesday, July 2nd, 2013

Can-Fite has obtained a US patent for its sexual performance drug

– Can-Fite Ceo Pnina Fishman – /By Ilan Shavit/ Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) has obtained a patent from the US Patent and Trademark Office for its CF602 drug, which More...

Wordpress site Developed by Fixing WordPress Problems